Uzbekinvest Acquires Risk and Capital Modelling Capabilities From Ultimate Risk Solutions Which Helped Them Attain Stable AM Best Rating
Ultimate Risk Solutions (“URS”) is proud to announce its important contribution into assisting Uzbekinvest Export-Import Insurance Company of Uzbekistan (“Uzbekinvest”) in attaining their stable AM Best credit rating. Through the development of advanced risk models of Uzbekinvest’s insurance and reinsurance lines of business, including catastrophe risk, URS has contributed significantly to this achievement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730430996/en/
Uzbekinvest acquires risk and capital modelling capabilities from Ultimate Risk Solutions (URS) which helped them attain stable AM Best rating (Graphic: Business Wire)
AM Best, a global credit rating agency specializing in the insurance industry, has revised the outlook for Uzbekinvest from negative to stable. The Financial Strength Rating remains at B (Fair), and the Long-Term Issuer Credit Rating at “bb” (Fair). This positive shift reflects Uzbekinvest’s enhanced risk-adjusted capitalization, in part attributed to the sophisticated risk modelling and probable maximum loss estimation facilitated by URS.
URS’s expertise in risk analysis and modelling has been instrumental in this process, showcasing the company’s commitment to delivering tailored risk solutions that enhance the financial stability and performance of its clients.
“Our company, which is the largest insurance and reinsurance provider in Uzbekistan, has made significant advances in the international markets, and is striving to become a global player closely working with AM Best during the process. Risk and capital modelling capabilities offered by URS technologies allow us to keep an eye on the solvency and stability of our global risk portfolio as it continues to grow,” said Rustam Azimov, General Director of Uzbekinvest.
“We are delighted to have supported Uzbekinvest in their journey towards improved financial strength and stability,” said Alex Bushel, Founder and CEO at Ultimate Risk Solutions. “Our team’s dedication to developing sophisticated and comprehensive risk models underscores our mission to empower our clients with the tools necessary for effective risk management and sustainable growth.”
This collaboration marks a significant milestone for both Uzbekinvest and URS, highlighting the importance of innovative risk management strategies in the insurance sector. As URS continues to pioneer in risk modelling and analysis, it remains committed to helping its clients navigate the complexities of risk with confidence and precision.
About Uzbekinvest:
Uzbekinvest Export-Import Insurance Company JSC is a prominent insurance and reinsurance provider in Uzbekistan and globally. The company is committed to offering reliable and comprehensive insurance and reinsurance solutions to its clients, backed by leading modern technologies and a team of dedicated professionals. This company manages total assets valued at USD 164 million and maintains substantial reserves amounting more than USD 106 million, indicating strong financial stability and capacity to cover potential liabilities. Uzbekinvest boasts a robust global footprint, handling risks from 132 countries. It maintains strong partnerships with major reinsurance companies such as Munich Re, Swiss Re, Allianz, Zurich Insurance Company and collaborates with top-tier broking firms including AON, Willis, Marsh, Guy Carpenter, Howden and others to enhance its market reach and service capabilities.
About Ultimate Risk Solutions:
Ultimate Risk Solutions (URS) is a leading provider of risk modelling and analysis technologies and services, offering advanced solutions for insurance companies and financial institutions globally. With a focus on innovation and precision, URS delivers technologies that help clients enhance their risk management practices and achieve their strategic objectives.
Link to AM Best press release regarding revised Uzbekinvest rating outlook:
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730430996/en/
Contacts
Sasha Kuznetsov, URS Marketing and Communications Lead | akuznetsov@ultirisk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 16:00:00 EET | Press release
Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom